Ten reasons why it is worth to use atorvastatin Review article
Article Sidebar
Published:
Sep 30, 2014
Keywords:
hyperlipidaemia, atorvastatin, hypolipidemic treatment
Main Article Content
Abstract
Ten reasons to use atorvastatin were described. Specific groups of patients that particulary benefit from atorvastatin treatment were indicated. Reasons were proposed mainly based on large, randomized, clinical trials, on the grounds of which experts from European Society of Cardiology formulated current guidelines for patients with cardiovascular diseases.
Article Details
How to Cite
Możeńska , O. (2014). Ten reasons why it is worth to use atorvastatin. Medycyna Faktow (J EBM), 7(3(24), 31-34. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2350
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Armitage J.: The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781-1790.
2. European Association for Cardiovascular & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32(14): 1769-1818.
3. Pasceri V., Patti G., Nusca A. et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110(6): 674-678.
4. Mills E.J., O’Regan C., Eyawo O. et al.: Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 2011; 32(11): 1409-1415.
5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
6. Sever P.S., Poulter N.R., Dahlof B. et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo- Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-1157.
7. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007; 28(12): 1462-1536.
9. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350(15): 1495-1504.
10. Aung P.P., Maxwell H.G., Jepson R.G. et al.: Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane database of systematic reviews 2007(4): CD000123.
11. European Stroke O., Tendera M., Aboyans V., Bartelink M.L. et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(22): 2851-2906.
12. Amarenco P., Labreuche J.: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology 2009; 8(5): 453-463.
13. Elis A., Zhou R., Stein E.A.: Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiology in the Young 2014; 24(3): 437-441.
14. Lario F.C., Miname M.H., Tsutsui J.M. et al.: Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis. Echocardiography 2013; 30(1): 64-71.
15. Wu C.K., Yang Y.H., Lin T.T. et al.: Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. Journal of Internal Medicine 2014.
2. European Association for Cardiovascular & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32(14): 1769-1818.
3. Pasceri V., Patti G., Nusca A. et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110(6): 674-678.
4. Mills E.J., O’Regan C., Eyawo O. et al.: Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 2011; 32(11): 1409-1415.
5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
6. Sever P.S., Poulter N.R., Dahlof B. et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo- Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-1157.
7. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007; 28(12): 1462-1536.
9. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350(15): 1495-1504.
10. Aung P.P., Maxwell H.G., Jepson R.G. et al.: Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane database of systematic reviews 2007(4): CD000123.
11. European Stroke O., Tendera M., Aboyans V., Bartelink M.L. et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(22): 2851-2906.
12. Amarenco P., Labreuche J.: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology 2009; 8(5): 453-463.
13. Elis A., Zhou R., Stein E.A.: Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiology in the Young 2014; 24(3): 437-441.
14. Lario F.C., Miname M.H., Tsutsui J.M. et al.: Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis. Echocardiography 2013; 30(1): 64-71.
15. Wu C.K., Yang Y.H., Lin T.T. et al.: Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. Journal of Internal Medicine 2014.